1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1naresh
Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)


Table 1: 
Clinical course of myelopathy
Symptoms at presentationaParesthesia lower limbs: 6/10 (60%)
Pain (back and legs): 5/10 (50%)
Lower extremity motor weakness: 7/10 (70%)
Urinary incontinence: 4/10 (40%)
Bowel incontinence: 2/10 (20%)
Treatment receivedSteroids: 9
IvIg: 1
Hyperbaric oxygen: 2
Plasmapheresis: 2
Bevacizumab (Avastin): 1
Mean duration of clinical follow-up (mo)22 (range: 4–162)
Clinical course on follow-up (available in 7 patients)Improved with some sequelae: 5
Progressive: 2
Resolved: 0
  • Note:—IvIg indicates intravenous immunoglobulin.
  • ↵a Detailed clinical examination was not available for 1 patient. Hence, only 10 patients were included for evaluation of the clinical course.